EHA 2024: Updates in the Treatment of CLL - Episode 3
Frontline BTKi Selection
Key opinion leaders examine the use of continuous Bruton's tyrosine kinase inhibitor therapy in front-line treatment, strategies for sequencing therapies, and the potential incorporation of obinutuzumab into treatment regimens.
- Dr Lamanna: When considering continuous BTKi therapy in the front-line setting, how do you select among available treatment options?
- How do you select patients for acala vs zanu?
- In which patients would you consider the addition of obinutuzumab?
- Dr Danilov: How important is long-term efficacy and safety data when making informed treatment decisions and how may these data shape your overall treatment approach?
- Dr Coombs asks about Frontline use??
- ELEVATE-TN – 6-yr follow up (Sharman, et al. ASH 2023. Abstract 636)
- SEQUOIA – Extended Follow-up (Munir, et al. Hemasphere 2023)
Related Content:
